SARS-CoV-2 Vaccine Impact in Antibody Response
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 1334
Special Issue Editor
2. INSERM UMR-S 1109 LabEx TRANSPLANTEX, Strasbourg University, 67000 Strasbourg, France
Interests: SARS-CoV-2; BK virus; kidney; transplantation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Since the beginning of the COVID-19 pandemic, many anti-SARS-CoV-2 vaccine platforms have been developed and used. Anti-SARS-CoV-2 vaccines have significantly reduced the morbidity and mortality associated with this viral infection. Unfortunately, a short-term decline in antibody titer and the emergence of new variants of concern appear to reduce vaccine efficacy and have re-exposed the vaccinated population to COVID-19. Additionally, the vaccine response remains weak in the immunocompromised population, who are especially exposed to severe forms of COVID-19. Today, there are many data regarding anti-SARS-CoV-2 vaccinations in the literature, but many questions remain among them: What is the impact of bivalent vaccines on antibody response? What is the best vaccination schedule to optimize the immune response? Can we define a neutralizing antibody threshold or a protective antibody titer to guide vaccine strategy? What strategies should be adopted in immunocompromised patients in order to improve the vaccine response? What is the effectiveness of new vaccines, such as recombinant protein vaccines or intranasal vaccines? What are the short- and long-term vaccine antibody responses in children? Furthermore, as the pandemic evolves, other questions will arise.
For this Special Issue, we invite submissions in the form of original research articles, reviews or brief reports that address these issues and more generally the humoral response to SARS-CoV-2 vaccines.
Dr. Ilies Benotmane
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody response
- humoral response
- neutralizing antibody
- SARS-CoV-2
- COVID-19
- vaccine
- immune response
